ARBUTUS BIOPHARMA CORP's ticker is ABUS and the CUSIP is 03879J100. A total of 97 filers reported holding ARBUTUS BIOPHARMA CORP in Q3 2023. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,985 | -22.7% | 12,308 | -12.4% | 0.00% | – |
| Q2 2023 | $32,332 | -12.5% | 14,057 | +15.2% | 0.00% | – |
| Q1 2023 | $36,960 | +30.0% | 12,198 | 0.0% | 0.00% | – |
| Q4 2022 | $28,421 | +23.6% | 12,198 | 0.0% | 0.00% | – |
| Q3 2022 | $23,000 | -17.9% | 12,198 | +16.5% | 0.00% | – |
| Q2 2022 | $28,000 | +16.7% | 10,466 | +31.6% | 0.00% | – |
| Q1 2022 | $24,000 | -4.0% | 7,951 | +21.9% | 0.00% | – |
| Q4 2021 | $25,000 | -10.7% | 6,525 | 0.0% | 0.00% | – |
| Q3 2021 | $28,000 | +47.4% | 6,525 | +4.6% | 0.00% | – |
| Q2 2021 | $19,000 | +72.7% | 6,241 | +18.9% | 0.00% | – |
| Q2 2019 | $11,000 | -42.1% | 5,247 | 0.0% | 0.00% | – |
| Q1 2019 | $19,000 | -82.6% | 5,247 | -81.5% | 0.00% | – |
| Q4 2018 | $109,000 | -53.0% | 28,407 | +15.8% | 0.00% | – |
| Q3 2018 | $232,000 | +510.5% | 24,540 | +367.7% | 0.00% | – |
| Q2 2018 | $38,000 | – | 5,247 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 340,000 | $1,459,000 | 0.53% |
| RTW INVESTMENTS, LP | 4,733,323 | $20,306,000 | 0.31% |
| APIS CAPITAL ADVISORS, LLC | 70,000 | $300,000 | 0.29% |
| Hudson Bay Capital Management LP | 1,800,000 | $7,722,000 | 0.10% |
| COWEN AND COMPANY, LLC | 249,215 | $1,069,000 | 0.05% |
| Kerrisdale Advisers, LLC | 100,000 | $429,000 | 0.05% |
| Woodline Partners LP | 496,172 | $2,129,000 | 0.04% |
| Shay Capital LLC | 60,000 | $257,000 | 0.03% |
| Walleye Capital LLC | 231,037 | $991,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 212,700 | $912,000 | 0.02% |